Skip to main content
Top
Published in: The Patient - Patient-Centered Outcomes Research 2/2017

01-04-2017 | Review Article

Factors Affecting Patients’ Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants

Authors: Ekta Y. Pandya, Beata Bajorek

Published in: The Patient - Patient-Centered Outcomes Research | Issue 2/2017

Login to get access

Abstract

The role of the direct oral anticoagulants (DOACs) in practice has been given extensive consideration recently, albeit largely from the clinician’s perspective. However, the effectiveness and safety of using anticoagulants is highly dependent on the patient’s ability to manage and take these complex, high-risk medicines. This structured narrative review explores the published literature to identify the factors underpinning patients’ non-adherence to anticoagulants in atrial fibrillation (AF), and subsequently contemplates to what extent the DOACs might overcome the known challenges with traditional warfarin therapy. This review comprised a two-tier search of various databases and search platforms (CINAHL, Cochrane, Current Contents Connect, EMBASE, MEDLINE Ovid, EBSCO, PubMed, Google, Google Scholar) to yield 47 articles reporting patients perspectives on, and patients adherence to, anticoagulant therapy. The findings from the literature were synthesised under five interacting dimensions of adherence: therapy-related factors, patient-related factors, condition-related factors, social–economic factors and health system factors. Factors negatively affecting patients’ day-to-day lives (especially regular therapeutic drug monitoring, dose adjustments, dietary considerations) predominantly underpin a patient’s reluctance to take warfarin therapy, leading to non-adherence. Other patient-related factors underpinning non-adherence include patients’ perceptions and knowledge about the purpose of anticoagulation; understanding of the risks and benefits of therapy; socioeconomic status; and expectations of care from health professionals. In considering these findings, it is apparent that the DOACs may overcome some of the barriers to traditional warfarin therapy at least to an extent, particularly the need for regular monitoring, frequent dose adjustment and dietary considerations. However, their high cost, twice-daily dosing and gastrointestinal adverse effects may present additional challenges for patients and health systems. The review highlights the need to explicitly incorporate patients’ perspectives in decision-making processes for anticoagulant selection, to obtain optimum adherence and treatment outcomes. Further studies should explore resources that can better engage patients in decision making around the selection of anticoagulant therapy.
Appendix
Available only for authorised users
Literature
2.
go back to reference Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) study. Arch Intern Med. 2007;167(3):229–35.CrossRefPubMed Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) study. Arch Intern Med. 2007;167(3):229–35.CrossRefPubMed
3.
go back to reference Waterman AD, Milligan PE, Bayer L, Banet GA, Gatchel SK, Gage BF. Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm. 2004;61(12):1258–64.PubMed Waterman AD, Milligan PE, Bayer L, Banet GA, Gatchel SK, Gage BF. Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm. 2004;61(12):1258–64.PubMed
4.
go back to reference Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy. 2004;24(10):1311–6.CrossRefPubMed Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy. 2004;24(10):1311–6.CrossRefPubMed
5.
go back to reference Witt DM, Delate T, Clark NP, Garcia DA, Hylek EM, Ageno W, et al. Nonadherence with INR monitoring and anticoagulant complications. Thromb Res. 2013;132(2):e124–30.CrossRefPubMed Witt DM, Delate T, Clark NP, Garcia DA, Hylek EM, Ageno W, et al. Nonadherence with INR monitoring and anticoagulant complications. Thromb Res. 2013;132(2):e124–30.CrossRefPubMed
6.
go back to reference Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.CrossRefPubMed Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.CrossRefPubMed
7.
go back to reference Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.CrossRefPubMed Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.CrossRefPubMed
8.
go back to reference Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Medi. 2011;365(11):981–92.CrossRef Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Medi. 2011;365(11):981–92.CrossRef
10.
go back to reference Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013(1):464–70.PubMed Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013(1):464–70.PubMed
11.
go back to reference January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, ACC/AHA Task Force Members, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. J Am College Cardiol. 2014;130(23):2071–104. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, ACC/AHA Task Force Members, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. J Am College Cardiol. 2014;130(23):2071–104.
12.
go back to reference Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34(27):2094–106.CrossRefPubMed Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34(27):2094–106.CrossRefPubMed
13.
go back to reference Haynes RB, Devereaux P, Guyatt GH. Physicians’ and patients’ choices in evidence based practice: evidence does not make decisions, people do. BMJ. 2002;324(7350):1350.CrossRefPubMedPubMedCentral Haynes RB, Devereaux P, Guyatt GH. Physicians’ and patients’ choices in evidence based practice: evidence does not make decisions, people do. BMJ. 2002;324(7350):1350.CrossRefPubMedPubMedCentral
14.
go back to reference Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE. Patients’ perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract. 2004;5(1):15.CrossRefPubMedPubMedCentral Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE. Patients’ perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract. 2004;5(1):15.CrossRefPubMedPubMedCentral
15.
go back to reference Klaus K. Content analysis: an introduction to its methodology. Thousand Oaks: Sage Publications; 1980. Klaus K. Content analysis: an introduction to its methodology. Thousand Oaks: Sage Publications; 1980.
16.
go back to reference Kim JH, Kim GS, Kim EJ, Park S, Chung N, Chu SH. Factors affecting medication adherence and anticoagulation control in Korean patients taking warfarin. J Cardiovasc Nurs. 2011;26(6):466–74.CrossRefPubMed Kim JH, Kim GS, Kim EJ, Park S, Chung N, Chu SH. Factors affecting medication adherence and anticoagulation control in Korean patients taking warfarin. J Cardiovasc Nurs. 2011;26(6):466–74.CrossRefPubMed
17.
go back to reference Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother. 2005;39(4):632–6.CrossRefPubMed Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother. 2005;39(4):632–6.CrossRefPubMed
18.
go back to reference Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf. 2008;17(9):853–60.CrossRefPubMedPubMedCentral Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf. 2008;17(9):853–60.CrossRefPubMedPubMedCentral
19.
go back to reference Cruess DG, Localio AR, Platt AB, Brensinger CM, Christie JD, Gross R, et al. Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics. Int J Behav Med. 2010;17(1):33–42.CrossRefPubMedPubMedCentral Cruess DG, Localio AR, Platt AB, Brensinger CM, Christie JD, Gross R, et al. Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics. Int J Behav Med. 2010;17(1):33–42.CrossRefPubMedPubMedCentral
20.
go back to reference Orensky IA, Holdford DA. Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy. 2005;25(12):1801–8.CrossRefPubMed Orensky IA, Holdford DA. Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy. 2005;25(12):1801–8.CrossRefPubMed
21.
go back to reference Schauer DP, Moomaw CJ, Wess M, Webb T, Eckman MH. Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. J Gen Intern Med. 2005;20(12):1114–9.CrossRefPubMedPubMedCentral Schauer DP, Moomaw CJ, Wess M, Webb T, Eckman MH. Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. J Gen Intern Med. 2005;20(12):1114–9.CrossRefPubMedPubMedCentral
22.
go back to reference Kääriäinen M, Paukama M, Kyngäs H. Adherence with health regimens of patients on warfarin therapy. J Clin Nurs. 2013;22(1–2):89–96.CrossRefPubMed Kääriäinen M, Paukama M, Kyngäs H. Adherence with health regimens of patients on warfarin therapy. J Clin Nurs. 2013;22(1–2):89–96.CrossRefPubMed
24.
go back to reference Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331–42.CrossRefPubMed Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331–42.CrossRefPubMed
25.
go back to reference Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006;5(3):101–17.CrossRefPubMedPubMedCentral Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006;5(3):101–17.CrossRefPubMedPubMedCentral
26.
go back to reference Gehlbach SH. Interpreting the medical literature. 3rd ed. New York: McGraw-Hill, Health Professions Division; 1993. Gehlbach SH. Interpreting the medical literature. 3rd ed. New York: McGraw-Hill, Health Professions Division; 1993.
28.
go back to reference Day R. How to write and publish a scientific paper, 5th ed. Phoenix: Oryx; 1998. Day R. How to write and publish a scientific paper, 5th ed. Phoenix: Oryx; 1998.
29.
go back to reference Thomas J, Harden A, Newman M. Synthesis: combining results systematically and appropriately. In: Gough D, Oliver S, Thomas J, editors. An introduction to systematic reviews. London: Sage Publications Ltd; 2012. p. 179–227. Thomas J, Harden A, Newman M. Synthesis: combining results systematically and appropriately. In: Gough D, Oliver S, Thomas J, editors. An introduction to systematic reviews. London: Sage Publications Ltd; 2012. p. 179–227.
30.
go back to reference Snilstveit B, Oliver S, Vojtkova M. Narrative approaches to systematic review and synthesis of evidence for international development policy and practice. J Dev Effect. 2012;4(3):409–29.CrossRef Snilstveit B, Oliver S, Vojtkova M. Narrative approaches to systematic review and synthesis of evidence for international development policy and practice. J Dev Effect. 2012;4(3):409–29.CrossRef
31.
go back to reference Barcellona D, Contu P, Sorano GG, Pengo V, Marongiu F. The management of oral anticoagulant therapy: the patient’s point of view. Thromb Haemost. 2000;83(1):49–53.PubMed Barcellona D, Contu P, Sorano GG, Pengo V, Marongiu F. The management of oral anticoagulant therapy: the patient’s point of view. Thromb Haemost. 2000;83(1):49–53.PubMed
32.
go back to reference Wild D, Murray M, Donatti C. Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. Expert Rev Pharmacoecon Outcomes Res. 2009;9(5):467–74.CrossRefPubMed Wild D, Murray M, Donatti C. Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. Expert Rev Pharmacoecon Outcomes Res. 2009;9(5):467–74.CrossRefPubMed
34.
go back to reference Tan K, Tallon E, Noone I, Hughes G, O’Shea D, Crowe M. Difficulties encountered by the very elderly with atrial fibrillation on warfarin attending an outpatient anticoagulant monitoring service. Eur Geriatr Med. 2012;3(2):78–81.CrossRef Tan K, Tallon E, Noone I, Hughes G, O’Shea D, Crowe M. Difficulties encountered by the very elderly with atrial fibrillation on warfarin attending an outpatient anticoagulant monitoring service. Eur Geriatr Med. 2012;3(2):78–81.CrossRef
35.
go back to reference Lancaster TR, Singer DE, Sheehan MA, Oertel LB, Maraventano SW, Hughes RA, et al. The impact of long-term warfarin therapy on quality of life: evidence from a randomized trial. Arch Intern Med. 1991;151(10):1944–9.CrossRefPubMed Lancaster TR, Singer DE, Sheehan MA, Oertel LB, Maraventano SW, Hughes RA, et al. The impact of long-term warfarin therapy on quality of life: evidence from a randomized trial. Arch Intern Med. 1991;151(10):1944–9.CrossRefPubMed
36.
go back to reference Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with anticoagulation: a case-control study. Am J Med. 1997;103(1):11–7.CrossRefPubMed Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with anticoagulation: a case-control study. Am J Med. 1997;103(1):11–7.CrossRefPubMed
37.
go back to reference Ansell JE, Maynard GA, Varga EA, Friedman RJ, Brownstein AP. Survey of atrial fibrillation patients demonstrates gaps in awareness of stroke risk and perceived barriers associated with anticoagulation therapy. Am J Hematol. 2012;87:S157–8. Ansell JE, Maynard GA, Varga EA, Friedman RJ, Brownstein AP. Survey of atrial fibrillation patients demonstrates gaps in awareness of stroke risk and perceived barriers associated with anticoagulation therapy. Am J Hematol. 2012;87:S157–8.
38.
go back to reference Almeida Gde Q, Noblat Lde A, Passos LC, do Nascimento HF. Quality of life analysis of patients in chronic use of oral anticoagulant: an observational study. Health Qual Life Outcomes. 2011;9:91. doi:10.1186/1477-7525-9-91. Almeida Gde Q, Noblat Lde A, Passos LC, do Nascimento HF. Quality of life analysis of patients in chronic use of oral anticoagulant: an observational study. Health Qual Life Outcomes. 2011;9:91. doi:10.​1186/​1477-7525-9-91.
40.
go back to reference Moia M, Mantovani LG, Carpenedo M, Scalone L, Monzini MS, Cesana G, et al. Patient preferences and willingness to pay for different options of anticoagulant therapy. Intern Emerg Med. 2013;8(3):237–43.CrossRefPubMed Moia M, Mantovani LG, Carpenedo M, Scalone L, Monzini MS, Cesana G, et al. Patient preferences and willingness to pay for different options of anticoagulant therapy. Intern Emerg Med. 2013;8(3):237–43.CrossRefPubMed
41.
go back to reference Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation–semi-qualitative analysis of older patients’ views about stroke prevention and the use of warfarin. Age Ageing. 2004;33(6):608–11. doi:10.1093/ageing/afh202.CrossRefPubMed Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation–semi-qualitative analysis of older patients’ views about stroke prevention and the use of warfarin. Age Ageing. 2004;33(6):608–11. doi:10.​1093/​ageing/​afh202.CrossRefPubMed
42.
go back to reference Gebler-Hughes ES, Kemp L, Bond MJ. Patients’ perspectives regarding long-term warfarin therapy and the potential transition to new oral anticoagulant therapy. Ther Adv Drug Saf. 2014;5(6):220–8.CrossRefPubMedPubMedCentral Gebler-Hughes ES, Kemp L, Bond MJ. Patients’ perspectives regarding long-term warfarin therapy and the potential transition to new oral anticoagulant therapy. Ther Adv Drug Saf. 2014;5(6):220–8.CrossRefPubMedPubMedCentral
43.
go back to reference Parker CS, Chen Z, Price M, Gross R, Metlay JP, Christie JD, et al. Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med. 2007;22(9):1254–9.CrossRefPubMedPubMedCentral Parker CS, Chen Z, Price M, Gross R, Metlay JP, Christie JD, et al. Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med. 2007;22(9):1254–9.CrossRefPubMedPubMedCentral
45.
go back to reference Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefPubMed Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefPubMed
46.
go back to reference Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49(5):761–72.CrossRefPubMed Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49(5):761–72.CrossRefPubMed
47.
go back to reference Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs. 2014;14(3):175–89.CrossRefPubMed Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs. 2014;14(3):175–89.CrossRefPubMed
48.
go back to reference Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2011;106(5):868–76.CrossRefPubMed Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2011;106(5):868–76.CrossRefPubMed
50.
go back to reference Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.CrossRefPubMed Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.CrossRefPubMed
51.
go back to reference January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Conti JB, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.CrossRefPubMed January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Conti JB, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.CrossRefPubMed
52.
go back to reference Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Balancing risk versus benefit: the elderly patient’s perspective on warfarin therapy. Pharm Pract (Granada). 2009;7(2):113–23.CrossRefPubMedPubMedCentral Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Balancing risk versus benefit: the elderly patient’s perspective on warfarin therapy. Pharm Pract (Granada). 2009;7(2):113–23.CrossRefPubMedPubMedCentral
53.
go back to reference Vaughan Sarrazin MS, Cram P, Mazur A, Ward M, Reisinger HS. Patient perspectives of dabigatran: analysis of online discussion forums. Patient. 2014;7(1):47–54. doi:10.1007/s40271-013-0027-y. Vaughan Sarrazin MS, Cram P, Mazur A, Ward M, Reisinger HS. Patient perspectives of dabigatran: analysis of online discussion forums. Patient. 2014;7(1):47–54. doi:10.​1007/​s40271-013-0027-y.
54.
56.
go back to reference Thorne K, Jayathissa S, Dee S, Briggs N, Taylor J, Reid S, et al. Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice. Intern Med J. 2014;44(3):261–5. doi:10.1111/imj.12370.CrossRefPubMed Thorne K, Jayathissa S, Dee S, Briggs N, Taylor J, Reid S, et al. Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice. Intern Med J. 2014;44(3):261–5. doi:10.​1111/​imj.​12370.CrossRefPubMed
58.
go back to reference Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost. 2013;11(7):1295–9.CrossRefPubMed Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost. 2013;11(7):1295–9.CrossRefPubMed
59.
go back to reference Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Med J Aust. 2007;186(4):175–80.PubMed Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Med J Aust. 2007;186(4):175–80.PubMed
60.
go back to reference Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31(3):326–43.CrossRefPubMed Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31(3):326–43.CrossRefPubMed
65.
go back to reference Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health Administration. Am Heart J. 2014;167(6):810–7.CrossRefPubMed Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health Administration. Am Heart J. 2014;167(6):810–7.CrossRefPubMed
67.
go back to reference Brighton T. New oral anticoagulant drugs–mechanisms of action. Aust Prescr. 2010;33(2):38–41.CrossRef Brighton T. New oral anticoagulant drugs–mechanisms of action. Aust Prescr. 2010;33(2):38–41.CrossRef
68.
go back to reference Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285–95.CrossRefPubMed Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285–95.CrossRefPubMed
69.
go back to reference Spinler SA, Willey VJ. A patient’s guide to taking dabigatran etexilate. Circulation. 2011;124(8):e209–11.CrossRefPubMed Spinler SA, Willey VJ. A patient’s guide to taking dabigatran etexilate. Circulation. 2011;124(8):e209–11.CrossRefPubMed
70.
go back to reference Cios D, Fanikos J. Rivaroxaban to prevent pulmonary embolism after hip or knee replacement. Circulation. 2012;125(14):e542–4.CrossRefPubMed Cios D, Fanikos J. Rivaroxaban to prevent pulmonary embolism after hip or knee replacement. Circulation. 2012;125(14):e542–4.CrossRefPubMed
73.
go back to reference Hong C, Kim S, Curnew G, Schulman S, Pullenayegum E, Holbrook A. Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation. J Popul Ther Clin Pharmacol. 2013;20(3):e229–37.PubMed Hong C, Kim S, Curnew G, Schulman S, Pullenayegum E, Holbrook A. Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation. J Popul Ther Clin Pharmacol. 2013;20(3):e229–37.PubMed
74.
go back to reference Sjölander M, Eriksson M, Glader E-L. The association between patients’ beliefs about medicines and adherence to drug treatment after stroke: a cross-sectional questionnaire survey. BMJ Open. 2013;3(9):e003551.CrossRefPubMedPubMedCentral Sjölander M, Eriksson M, Glader E-L. The association between patients’ beliefs about medicines and adherence to drug treatment after stroke: a cross-sectional questionnaire survey. BMJ Open. 2013;3(9):e003551.CrossRefPubMedPubMedCentral
75.
go back to reference Elliott RA. Appropriate use of dose administration aids. Aust Prescr. 2014;37:46–50.CrossRef Elliott RA. Appropriate use of dose administration aids. Aust Prescr. 2014;37:46–50.CrossRef
76.
go back to reference Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GY. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme: the West Birmingham Atrial Fibrillation Project. Int J Cardiol. 2006;110(3):354–8.CrossRefPubMed Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GY. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme: the West Birmingham Atrial Fibrillation Project. Int J Cardiol. 2006;110(3):354–8.CrossRefPubMed
77.
go back to reference Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy the West Birmingham atrial fibrillation project. Stroke. 2002;33(1):238–42.CrossRefPubMed Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy the West Birmingham atrial fibrillation project. Stroke. 2002;33(1):238–42.CrossRefPubMed
78.
go back to reference Casais P, Meschengieser SS, Sanchez-Luceros A, Lazzari MA. Patients’ perceptions regarding oral anticoagulation therapy and its effect on quality of life. Curr Med Res Opin. 2005;21(7):1085–90. doi:10.1185/030079905X50624.CrossRefPubMed Casais P, Meschengieser SS, Sanchez-Luceros A, Lazzari MA. Patients’ perceptions regarding oral anticoagulation therapy and its effect on quality of life. Curr Med Res Opin. 2005;21(7):1085–90. doi:10.​1185/​030079905X50624.CrossRefPubMed
79.
80.
go back to reference Ghijben P, Lancsar E, Zavarsek S. Preferences for oral anticoagulants in atrial fibrillation: a best–best discrete choice experiment. Pharmacoeconomics. 2014;32(11):1115–27.CrossRefPubMed Ghijben P, Lancsar E, Zavarsek S. Preferences for oral anticoagulants in atrial fibrillation: a best–best discrete choice experiment. Pharmacoeconomics. 2014;32(11):1115–27.CrossRefPubMed
81.
go back to reference Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72.CrossRefPubMed Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72.CrossRefPubMed
82.
go back to reference Nessel C, Mahaffey K, Piccini J, Pan G, Patel M, Becker R, et al. Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKET AF Trial [abstract]. Chest. 2012;142(4_MeetingAbstracts):84A-A. Nessel C, Mahaffey K, Piccini J, Pan G, Patel M, Becker R, et al. Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKET AF Trial [abstract]. Chest. 2012;142(4_MeetingAbstracts):84A-A.
83.
go back to reference Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013;2013:640723.CrossRefPubMedPubMedCentral Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013;2013:640723.CrossRefPubMedPubMedCentral
85.
go back to reference Ho PM, Bryson CL, Rumsfeld JS. Medication adherence its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35.CrossRefPubMed Ho PM, Bryson CL, Rumsfeld JS. Medication adherence its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35.CrossRefPubMed
86.
go back to reference Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE, et al. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace. 2010;12(5):626–33.CrossRefPubMedPubMedCentral Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE, et al. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace. 2010;12(5):626–33.CrossRefPubMedPubMedCentral
87.
go back to reference LaMori JC, Mody SH, Gross HJ, daCosta DiBonaventura M, Patel AA, Schein JR, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53–62. doi:10.1177/1753944712464101. LaMori JC, Mody SH, Gross HJ, daCosta DiBonaventura M, Patel AA, Schein JR, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53–62. doi:10.​1177/​1753944712464101​.
88.
go back to reference Sánchez E, Vidán MT, Serra JA, Fernández-Avilés F, Bueno H. Prevalence of geriatric syndromes and impact on clinical and functional outcomes in older patients with acute cardiac diseases. Heart. 2011;97(19):1602–6.CrossRefPubMed Sánchez E, Vidán MT, Serra JA, Fernández-Avilés F, Bueno H. Prevalence of geriatric syndromes and impact on clinical and functional outcomes in older patients with acute cardiac diseases. Heart. 2011;97(19):1602–6.CrossRefPubMed
90.
go back to reference Gibson J, Coupe J, Watkins C. Medication adherence post-stroke: an exploratory study of stroke unit nurses’ perspectives of potential problems affecting patients early after discharge. Int J Stroke. 2014;9(Suppl. 4):7. Gibson J, Coupe J, Watkins C. Medication adherence post-stroke: an exploratory study of stroke unit nurses’ perspectives of potential problems affecting patients early after discharge. Int J Stroke. 2014;9(Suppl. 4):7.
91.
92.
go back to reference Attaya S, Bornstein T, Ronquillo N, Volgman R, Braun LT, Trohman R, et al. Study of warfarin patients investigating attitudes toward therapy change (SWITCH Survey). Am J Ther. 2012;19(6):432–5.CrossRefPubMed Attaya S, Bornstein T, Ronquillo N, Volgman R, Braun LT, Trohman R, et al. Study of warfarin patients investigating attitudes toward therapy change (SWITCH Survey). Am J Ther. 2012;19(6):432–5.CrossRefPubMed
93.
go back to reference Nelson WW, Song X, Coleman CI, Thomson E, Smith DM, Damaraju CV, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2014;30(12):2461–9. doi:10.1185/03007995.2014.933577.CrossRefPubMed Nelson WW, Song X, Coleman CI, Thomson E, Smith DM, Damaraju CV, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2014;30(12):2461–9. doi:10.​1185/​03007995.​2014.​933577.CrossRefPubMed
98.
go back to reference Protheroe J, Fahey T, Montgomery AA, Peters TJ. Effects of patients’ preferences on the treatment of atrial fibrillation: observational study of patient-based decision analysis. West J Med. 2001;174(5):311.CrossRefPubMedPubMedCentral Protheroe J, Fahey T, Montgomery AA, Peters TJ. Effects of patients’ preferences on the treatment of atrial fibrillation: observational study of patient-based decision analysis. West J Med. 2001;174(5):311.CrossRefPubMedPubMedCentral
99.
go back to reference Thomson RG, Eccles MP, Steen IN, Greenaway J, Stobbart L, Murtagh MJ, et al. A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial. Qual Saf Health Care. 2007;16(3):216–23. doi:10.1136/qshc.2006.018481.CrossRefPubMedPubMedCentral Thomson RG, Eccles MP, Steen IN, Greenaway J, Stobbart L, Murtagh MJ, et al. A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial. Qual Saf Health Care. 2007;16(3):216–23. doi:10.​1136/​qshc.​2006.​018481.CrossRefPubMedPubMedCentral
100.
go back to reference National Institute for Health and Care Excellence (NICE). Atrial fibrillation: medicines to help reduce your risk of a stroke—what are the options? London: NICE; 2014. National Institute for Health and Care Excellence (NICE). Atrial fibrillation: medicines to help reduce your risk of a stroke—what are the options? London: NICE; 2014.
101.
go back to reference Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision making in atrial fibrillation where we are and where we should be going. Circulation. 2014;129(6):704–10.CrossRefPubMed Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision making in atrial fibrillation where we are and where we should be going. Circulation. 2014;129(6):704–10.CrossRefPubMed
102.
go back to reference Robinson A, Thomson R. The potential use of decision analysis to support shared decision making in the face of uncertainty: the example of atrial fibrillation and warfarin anticoagulation. Qual Health Care. 2000;9(4):238–44.CrossRefPubMedPubMedCentral Robinson A, Thomson R. The potential use of decision analysis to support shared decision making in the face of uncertainty: the example of atrial fibrillation and warfarin anticoagulation. Qual Health Care. 2000;9(4):238–44.CrossRefPubMedPubMedCentral
103.
go back to reference Howitt AJ. Anticoagulation therapy for atrial fibrillation: Explaining patients' choices. Cardiovas rev r. 2000;21(10):527–31. Howitt AJ. Anticoagulation therapy for atrial fibrillation: Explaining patients' choices. Cardiovas rev r. 2000;21(10):527–31.
104.
go back to reference Michel J, Mundell D, Boga T, Sasse A. Dabigatran for anticoagulation in atrial fibrillation–early clinical experience in a hospital population and comparison to trial data. Heart, Lung Circ. 2013;22(1):50–5.CrossRef Michel J, Mundell D, Boga T, Sasse A. Dabigatran for anticoagulation in atrial fibrillation–early clinical experience in a hospital population and comparison to trial data. Heart, Lung Circ. 2013;22(1):50–5.CrossRef
105.
go back to reference Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the IN‐RANGE study. Pharmacoepidemiol drug saf. 2008;17(9):853-60.CrossRefPubMedPubMedCentral Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the IN‐RANGE study. Pharmacoepidemiol drug saf. 2008;17(9):853-60.CrossRefPubMedPubMedCentral
Metadata
Title
Factors Affecting Patients’ Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants
Authors
Ekta Y. Pandya
Beata Bajorek
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research / Issue 2/2017
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-016-0180-1

Other articles of this Issue 2/2017

The Patient - Patient-Centered Outcomes Research 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.